Breaking News Instant updates and real-time market news.

TRIL

Trillium Therapeutics

$4.75

-0.05 (-1.04%)

07:09
07/17/17
07/17
07:09
07/17/17
07:09

Trillium Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis started Trillium Therapeutics with a Buy rating and $7 price target. The analyst estimates that Trillium's lead product, TTI-621, which is currently being evaluated in Phase 1 and Phase 1b clinical studies, could be the first marketed CD47-targeting therapy and can generate peak sales of C$1.4B for hematologic and solid tumors.

  • 26

    Sep

TRIL Trillium Therapeutics
$4.75

-0.05 (-1.04%)

11/03/16
COWN
11/03/16
NO CHANGE
COWN
Outperform
Trillium Therapeutics weakness an overreaction, says Cowen
Cowen analyst Boris Peaker said weakness in Trillium Therapeutics due to safety concerns of DLT in Phase 1 dose-escalation trial is an overreaction. Peaker said Tiriium has advanced this study into expansion arms which we believe indicates they have found a therapeutic window and reiterates his Outperform rating.
08/03/16
08/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Curtiss-Wright (CW) initiated with a Market Perform at William Blair. 2. Alnylam (ALNY) initiated with an Overweight at Morgan Stanley. 3. Ionis Pharmaceuticals (IONS) initiated with an Equal Weight at Morgan Stanley. 4. Trillium Therapeutics (TRIL) initiated with a Buy at Ladenburg. 5. Zebra Technologies (ZBRA) initiated with a Buy at CLSA. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/03/16
LTCO
08/03/16
INITIATION
Target $18
LTCO
Buy
Trillium Therapeutics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Trillium Therapeutics with a Buy rating and $18 price target. The analyst views Trillium as an attractive investment opportunity in the immuno-oncology space.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.